Melane Sampson, Author at BioTuesdays

Executive Moves

Modivcare appoints Daniel Silvers to BOD; three BOD members resign

Modivcare (NASDAQ:MODV) announced that it has appointed Daniel Silvers to its board of directors (BOD), and board members Craig Barbarosh, David Coulter, and Richard Kerley have resigned, effective April 24, 2025. Mr...

April 25, 2025

Developments

Polyrizon reports positive safety study of allergy blocker

Polyrizon (NASDAQ:PLRZ) announced the successful preliminary safety study of a formulation of its PL-14 Allergy Blocker, advancing the product’s development path. According to Polyrizon, the study, designed to assess...

April 25, 2025

Developments

Ekso names Bionic P&O as first Ekso Indego Personal distributor within the orthotics and prosthetics industry

Ekso Bionics Holdings (NASDAQ:EKSO) announced it has selected Bionic Prosthetics & Orthotics Group (Bionic P&O) as a non-exclusive distributor of its Ekso Indego Personal device—the alliance marking Ekso’s first...

April 23, 2025

Developments

FDA clears Aclaris’ IND application for ATI-052 trial

Aclaris Therapeutics (NASDAQ:ACRS) announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1a/1b trial of ATI-052—expected to launch in Q2 of this year. According to Aclaris, the...

April 22, 2025

Developments

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients. According to Atossa, the patent...

April 22, 2025

Developments

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET...

April 17, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

Developments

Ironwood reports updates on apraglutide following FDA interaction

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced that a confirmatory Phase 3 trial evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and dependence on parenteral support, is a requirement...

April 14, 2025

Executive Moves

Verano names Richard Tarapchak as CFO

Verano Holdings (Cboe CA:VRNO; OTCQX:VRNOF) announced that it has promoted Richard Tarapchak to chief financial officer (CFO), succeeding Brett Summerer, who has resigned. Mr. Tarapchak brings more than 30 years of...

April 14, 2025

Developments

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine. According to...

April 11, 2025

Author - Melane Sampson

Modivcare appoints Daniel Silvers to BOD; three BOD members resign

Polyrizon reports positive safety study of allergy blocker

Ekso names Bionic P&O as first Ekso Indego Personal distributor within the orthotics and prosthetics industry

FDA clears Aclaris’ IND application for ATI-052 trial

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Arch advancing game-changing therapies for global kidney care

Ironwood reports updates on apraglutide following FDA interaction

Verano names Richard Tarapchak as CFO

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Subscribe